Postbiotics vs breast cancer cells. Postbiotics Win!
Published today A peer-reviewed study in Molecules (MDPI), published November 15, 2026, tested postbiotics from Lactiplantibacillus plantarum and Bifidobacterium longum on human breast cancer cell lines MCF-7 and MDA-MB-231.
Both postbiotics significantly reduced the viability and proliferative potential of the cancer cells - up to 60% reduction at the highest dose - while showing no significant effect on non-tumor HaCaT skin cells, with the effects linked to increased oxidative stress, apoptosis, cell-cycle changes, and reduced migration.
This is laboratory work in cell lines only: no animal or human data, and nothing here supports any use in patients.
An Evaluation of the Biological Effects of Lactiplantibacillus plantarum and Bifidobacterium longum Postbiotics on Human Breast Cancer Cell Lines
Link:
显示更多